SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-018537
Filing Date
2023-03-08
Accepted
2023-03-08 16:05:58
Documents
15
Period of Report
2023-03-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea174835-8k_jasper.htm   iXBRL 8-K 33200
2 PRESS RELEASE, DATED MARCH 8, 2023 ea174835ex99-1_jasper.htm EX-99.1 76668
3 GRAPHIC ex99-1_001.jpg GRAPHIC 17410
  Complete submission text file 0001213900-23-018537.txt   366248

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE jspr-20230308.xsd EX-101.SCH 4133
5 XBRL DEFINITION FILE jspr-20230308_def.xml EX-101.DEF 26833
6 XBRL LABEL FILE jspr-20230308_lab.xml EX-101.LAB 37093
7 XBRL PRESENTATION FILE jspr-20230308_pre.xml EX-101.PRE 25457
9 EXTRACTED XBRL INSTANCE DOCUMENT ea174835-8k_jasper_htm.xml XML 5873
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 23716161
SIC: 2836 Biological Products, (No Diagnostic Substances)